Malignant Hyperthermia: Difference between revisions

Jump to navigation Jump to search
no edit summary
No edit summary
No edit summary
Line 24: Line 24:


Indications for Malignant Hyperthermia Susceptibility Diagnostics in Patients without Adverse Anesthetic Events in the Era of Next-generation Sequencing.  Anesthesiology. 2022 Jun 1;136(6):940-953. PMID: 35285867
Indications for Malignant Hyperthermia Susceptibility Diagnostics in Patients without Adverse Anesthetic Events in the Era of Next-generation Sequencing.  Anesthesiology. 2022 Jun 1;136(6):940-953. PMID: 35285867
[https://pubs.asahq.org/anesthesiology/article/136/6/940/135870/Referral-Indications-for-Malignant-Hyperthermia Referral Indications for Malignant Hyperthermia Susceptibility Diagnostics in Patients without Adverse Anesthetic Events in the Era of Next-generation Sequencing]


[https://www.bjanaesthesia.org/article/S0007-0912(22)00496-2/fulltext Functional analysis of RYR1 variants in patients with confirmed susceptibility to malignant hyperthermia]
[https://www.bjanaesthesia.org/article/S0007-0912(22)00496-2/fulltext Functional analysis of RYR1 variants in patients with confirmed susceptibility to malignant hyperthermia]

Navigation menu